Cart
sales@molnova.com
Ensituximab
CAS No. 1092658-06-4
Ensituximab( —— )
Catalog No. M36883 CAS No. 1092658-06-4
Ensituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 472 | In Stock |
|
| 10MG | 757 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEnsituximab
-
NoteResearch use only, not for human use.
-
Brief DescriptionEnsituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic cancer.
-
DescriptionEnsituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1092658-06-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Richard D Kim, et al. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15;26(14):3557-3564. ?
molnova catalog
related products
-
SBI993
SBI993 is an analog of SBI-477 and can be used as a biomarker to confirm the expected action of MondoA target gene expression in vivo. SBI993 reduces muscle TAG levels and hepatic steatosis.
-
Lingdolinurad
Lingdolinurad is a uric acid transporter protein inhibitor targeting hURAT1 for the study of hyperuricemia or gout.
-
TM5441
TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor 1 (PAI-1).
